Tudor Investment Corp ET AL Decreases Stock Holdings in Progyny, Inc. $PGNY

Tudor Investment Corp ET AL reduced its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 46.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 250,849 shares of the company’s stock after selling 221,184 shares during the quarter. Tudor Investment Corp ET AL owned approximately 0.29% of Progyny worth $5,398,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in PGNY. Royal Bank of Canada lifted its stake in shares of Progyny by 384.8% during the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock worth $291,000 after purchasing an additional 10,340 shares during the last quarter. Amundi lifted its stake in shares of Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after purchasing an additional 5,817 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Progyny by 6.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock worth $5,630,000 after purchasing an additional 14,297 shares during the last quarter. Norges Bank purchased a new stake in shares of Progyny during the 2nd quarter worth $1,697,000. Finally, Invesco Ltd. lifted its stake in shares of Progyny by 37.4% during the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock worth $8,342,000 after purchasing an additional 103,253 shares during the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on PGNY. Wall Street Zen cut Progyny from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. Barclays decreased their price target on Progyny from $29.00 to $23.00 and set an “overweight” rating for the company in a research note on Friday, March 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a research note on Friday, March 27th. Truist Financial decreased their price target on Progyny from $34.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. Finally, BTIG Research decreased their price target on Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $27.91.

Insider Buying and Selling

In related news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the sale, the executive vice president directly owned 89,879 shares of the company’s stock, valued at $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 7,455 shares of company stock worth $129,515 over the last quarter. 9.40% of the stock is owned by company insiders.

Progyny Stock Performance

Shares of PGNY stock opened at $16.93 on Thursday. The stock’s 50-day simple moving average is $19.32 and its 200-day simple moving average is $22.06. The firm has a market capitalization of $1.33 billion, a PE ratio of 26.05, a P/E/G ratio of 0.96 and a beta of 0.99. Progyny, Inc. has a fifty-two week low of $16.28 and a fifty-two week high of $28.75.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $318.40 million for the quarter, compared to analyst estimates of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The company’s revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.42 earnings per share. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Sell-side analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current year.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.